164 related articles for article (PubMed ID: 34923762)
21. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
22. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
[No Abstract] [Full Text] [Related]
23. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
[No Abstract] [Full Text] [Related]
24. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
Dalapati T; Williams CA; Giorgi EE; Hurst JH; Herbek S; Chen JL; Kosman C; Rotta AT; Turner NA; Pulido N; Aquino JN; Pfeiffer TS; Rodriguez J; Fouda GG; Permar SR; Kelly MS
Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38548700
[TBL] [Abstract][Full Text] [Related]
25. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS
Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479
[TBL] [Abstract][Full Text] [Related]
26. Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
Du PX; Chang SS; Ho TS; Shih HC; Tsai PS; Syu GD
Virulence; 2024 Dec; 15(1):2351266. PubMed ID: 38717195
[No Abstract] [Full Text] [Related]
27. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.
Kaplonek P; Fischinger S; Cizmeci D; Bartsch YC; Kang J; Burke JS; Shin SA; Dayal D; Martin P; Mann C; Amanat F; Julg B; Nilles EJ; Musk ER; Menon AS; Krammer F; Saphire EO; Andrea Carfi ; Alter G
Immunity; 2022 Feb; 55(2):355-365.e4. PubMed ID: 35090580
[TBL] [Abstract][Full Text] [Related]
28. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.
Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A
EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205
[TBL] [Abstract][Full Text] [Related]
29. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2.
Brewer RC; Ramadoss NS; Lahey LJ; Jahanbani S; Robinson WH; Lanz TV
Nat Immunol; 2022 Jan; 23(1):33-39. PubMed ID: 34848871
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing Activity of BNT162b2-Elicited Serum.
Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
[No Abstract] [Full Text] [Related]
31. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
32. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
[TBL] [Abstract][Full Text] [Related]
33. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Front Immunol; 2022; 13():816220. PubMed ID: 35145522
[TBL] [Abstract][Full Text] [Related]
34. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
35. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants.
McCallum M; Walls AC; Sprouse KR; Bowen JE; Rosen LE; Dang HV; De Marco A; Franko N; Tilles SW; Logue J; Miranda MC; Ahlrichs M; Carter L; Snell G; Pizzuto MS; Chu HY; Van Voorhis WC; Corti D; Veesler D
Science; 2021 Dec; 374(6575):1621-1626. PubMed ID: 34751595
[TBL] [Abstract][Full Text] [Related]
36. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
37. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
[No Abstract] [Full Text] [Related]
38. CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses.
Woldemeskel BA; Dykema AG; Garliss CC; Cherfils S; Smith KN; Blankson JN
J Clin Invest; 2022 Mar; 132(5):. PubMed ID: 35061630
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
Koerber N; Priller A; Yazici S; Bauer T; Cheng CC; Mijočević H; Wintersteller H; Jeske S; Vogel E; Feuerherd M; Tinnefeld K; Winter C; Ruland J; Gerhard M; Haller B; Christa C; Zelger O; Roggendorf H; Halle M; Erber J; Lingor P; Keppler O; Zehn D; Protzer U; Knolle PA
Nat Commun; 2022 Jan; 13(1):153. PubMed ID: 35013191
[TBL] [Abstract][Full Text] [Related]
40. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
